Patient Support

Biopharma sponsorship of patient-support programs and treatments for rare diseases is growing, but gaps remain

New book attempts to cut through pharma’s patient-centric posturing and start a conversation about real, transformational change

Not quite specialty, not quite retail: Cost-effective access and support strategies for a growing, yet underserved, treatment market

The patient-first, pharmacy-first hub model optimizes outcomes and improves care journey for patients with rare disease

Disruption is the order of the day to create a more individual-centric hub experience from the patient’s point of view

A conversation with Ian Riches, head of patient solutions for Europe, Ashfield Engage

The need for supporting services in copay accumulator and best price areas

Creating positive experiences and other patient-focused strategies for sponsors to consider when planning and executing cancer studies

It's time to include hubs in the patient treatment journey

To unlock the full potential of new patient support tools, pharma companies must recognize the crucial role advanced analytics plays in facilitating enhanced patient engagement that yields improved adherence.

Aims to increase presence in affordability market

Taking advantage of new advances in tech-driven engagement to boost patient support and adherence

Finding new efficiencies, managing revenue and changing the dialogue on drug pricing

The services leverage technology to speed planning, budgeting and outsourcing

Rising tide of specialties lifts most providers’ businesses

Connectivity with patients drives pharma growth

Comprehensive patient care becomes the unifying theme of pharma hubs

Personality assessments identify the traits that enable some pharma researchers to ascend to leadership roles in industry

Industry is falling in love with the Apple iPad. Is it the right move for your company?

Today’s uncertain work environment obliges you to manage your career and financial status to keep your options open

Latest 10-year BLS projection sees moderate growth in US employment—except for ‘top executives’